Recent Updates
Recently added Catalysts
CHRS Positive Sentiment

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Tuesday, June 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Coherus Oncology and Zumutor Biologics have initiated a Phase 1 clinical study to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI, a next-generation PD-1 inhibitor. The first patient has been dosed, marking a significant step in the collaboration between the two companies. This study aims to assess the efficacy and safety of the combination treatment.
Price reaction · baseline $1.48 (2026-06-23T17:59:00.000Z) · hit during market hours · clean, no other CHRS news in the window
day 0 close · peak
-1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • First patient dosed in the Phase 1 study.
  • Collaboration between Coherus and Zumutor Biologics.
  • Evaluation of ZM008 in combination with a next-generation PD-1 inhibitor.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+136%
120-day peak, hindsight
Typical move
6.6%
average across 12 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
CHS-0214
Phase 3 · Rheumatoid Arthritis

Full Press Release Details

– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc.

Frequently Asked Questions

What is ZM008?

ZM008 is an anti-LLT1 monoclonal antibody being evaluated in clinical trials.

What is LOQTORZI?

LOQTORZI is a next-generation PD-1 inhibitor used in combination with ZM008.

Who is conducting the clinical trial?

The trial is a collaboration between Coherus Oncology and Zumutor Biologics.

What phase is the ZM008 study currently in?

The study is currently in Phase 1.

When was the first patient dosed?

The first patient was dosed on June 23, 2026.

ShareAdd on Google
Tags: CHRS Viatris Investor Conferences Healthcare Coherus Zumutor ZM008 LOQTORZI PD-1 inhibitor
Last updated: Jun 23, 2026

Biotech snapshot

Cash runway
$105M liquidity · $21M/mo burn
~5 mo
High dilution risk
Lead asset
CHS-0214Phase 3
Rheumatoid Arthritis →

Catalyst track record

+136%
best trade around CHRS's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for CHRS.

See every catalyst's timing & PoA →